In which clinical conditions should warfarin be preferred over non‑vitamin K antagonist oral anticoagulants (NOACs) and low‑molecular‑weight heparin (LMWH)?

Warfarin is Preferred Over NOACs and LMWH in Specific Clinical Conditions

Warfarin is the mandatory anticoagulant for patients with mechanical heart valves and should be strongly preferred for patients with moderate-to-severe mitral stenosis. 1

Absolute Indications for Warfarin

Mechanical Heart Valves

• All patients with mechanical prosthetic heart valves require warfarin 1, 2
• NOACs are contraindicated based on the RE-ALIGN trial, which demonstrated harm with dabigatran in this population 1
• Target INR varies by valve type and position:
  • St. Jude Medical bileaflet valve in aortic position: INR 2.5 (range 2.0-3.0)
  • Tilting disk or bileaflet valves in mitral position: INR 3.0 (range 2.5-3.5)
  • Caged ball or caged disk valves: INR 3.0 (range 2.5-3.5) plus aspirin 75-100 mg/day 2

Moderate-to-Severe Mitral Stenosis

• Warfarin is recommended for atrial fibrillation with mitral stenosis 1
• This is explicitly listed as an exclusion criterion for NOAC use in AF guidelines 1
• Target INR: 2.0-3.0 2

Strong Preference for Warfarin (Evidence-Based)

Antiphospholipid Antibody Syndrome (APS)

• Warfarin with INR goal 2-3 is recommended for VTE or stroke related to APS 3
• NOACs have not been adequately studied in this population and should be avoided pending further research 3

Bioprosthetic Heart Valves (First 3 Months)

• Warfarin with target INR 2.5 (range 2.0-3.0) is recommended:
  • For valves in the mitral position
  • For valves in the aortic position during the first 3 months post-insertion 2

Clinical Situations Where Warfarin May Be Preferred

End-Stage Renal Disease/Dialysis

• Edoxaban is contraindicated in end-stage renal disease or dialysis 1
• While apixaban may be reasonable in dialysis patients, warfarin remains an established option 1
• Warfarin does not require dose adjustment for renal failure 2

Extremes of Body Weight

• Patients at extremes of body weight are not optimal candidates for NOACs 4
• Warfarin allows for individualized dosing with INR monitoring 2

Malabsorption Conditions

• Patients with bariatric surgery, short gut syndrome, or other conditions affecting medication absorption should avoid NOACs 4
• Warfarin absorption can be monitored via INR 2

Drug Interactions

• Patients requiring strong CYP3A4 inhibitors/inducers or P-glycoprotein inhibitors/inducers should use warfarin or LMWH instead of NOACs 4
• Warfarin interactions are well-characterized and manageable with INR monitoring 2

Valvular Atrial Fibrillation

• Warfarin is recommended for AF with valvular heart disease 2, 5
• Target INR: 2.0-3.0 2

LMWH Preference Over Both Warfarin and NOACs

Active Malignancy with VTE

• LMWH continues to be recommended as first-line treatment for VTE in active cancer 5
• Growing evidence supports NOACs as an alternative, but LMWH remains guideline-preferred 5, 6

Intracranial Malignancy

• LMWH is recommended over warfarin or NOACs for patients with primary or metastatic brain tumors 3

Cerebral Venous Sinus Thrombosis (Acute Phase)

• LMWH is recommended in the acute setting, followed by at least 3 months of warfarin 3

Key Clinical Pitfalls

• Never use NOACs in mechanical valve patients - this is an absolute contraindication based on trial data showing harm 1
• Do not assume "bioprosthetic" means NOACs are safe immediately post-op - warfarin is needed for the first 3 months 2
• Moderate-to-severe mitral stenosis is often missed - always assess valve pathology before prescribing NOACs for AF 1
• APS requires specific testing - don't use NOACs in patients with lupus anticoagulant, anticardiolipin antibodies, or anti-β2 glycoprotein I antibodies 3